Not sure why this study was done...BUT... Tociiizumab was studied in 104 hand osteoarthritis and after 12 weeks, TCZ was equivalent to Placebo in achieving100mm VAS pain reduction (-9.9 vs -7.9), but TCZ had numerically more adverse events https://t.co/NYujNQbjvm